Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

Q15788 (NCOA1_HUMAN) Homo sapiens (Human)

Nuclear receptor coactivator 1 UniProtKBInterProSTRINGInteractive Modelling

1441 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3)

Available Structures

273 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Insight into the molecular recognition mechanism of the coactivator NCoA1 by STAT6 Heteromer
P42226;
257-385
Assess
LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Heteromer
P37231;
628-703
BRL;
Assess
Structural diversity in CBP p160 complexes Heteromer
P45481;
920-974
Assess
Crystal Structure of the SR12813-bound PXR/RXRalpha LBD Heterotetramer Complex Heteromer
O75469; P19793;
678-698
SRL;
Assess
PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Heteromer
P19793; P37231;
682-700
9CR;BRL;
Assess
Crystal Structure of PPAR Gamma with N-sulfonyl-2-indole carboxamide ligands Heteromer
P37231;
684-700
NSI;
Assess
Structure of pregnane X receptor in complex with a Sphingosine 1- Phosphate Receptor 1 Antagonist Heteromer
O75469;
682-698
D7E;
Assess
Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid Heteromer
P37231;
680-695
ET1;
Assess
THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMM… Heteromer
P19793; P37231;
685-700
9CR;570;
Assess
THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMM… Heteromer
P19793; P37231;
685-700
9CR;BRL;
Assess
Crystal structure of pregnane X receptor ligand binding domain complexed with JQ1 Heteromer
O75469;
682-697
JQ1;
Assess
The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalph… Heteromer
P19793; P37231;
685-700
9CR;544;
Assess
Molecular recognition of nitro-fatty acids by PPAR gamma Heteromer
P37231;
685-700
LNA;LNB;
Assess
Crystal structure of PPARgamma in complex with compound 13 Heteromer
P37231;
684-699
14R;
Assess
X-Ray Crystal Structure of LXR Ligand Binding Domain with 24(S),25-epoxycholesterol Heteromer
P55055;
682-697
CO1;
Assess
Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease Heteromer
Q13133;
682-696
668;SO4;
Assess
X-ray structure of GW3965 synthetic agonist bound to the LXR-alpha Heteromer
Q13133;
682-696
965;SO4;
Assess
Crystal Structure of the human PXR-LBD in complex with an SRC-1 coactivator peptide and SR12813 Heteromer
O75469;
682-696
SRL;
Assess
X-ray structure of benzisoxazole synthetic agonist bound to the LXR-alpha Heteromer
Q13133;
682-696
SO4;O90;
Assess
the crystal structure of the human PPARaplpha ligand binding domain in complex with a a-hydroxyimin… Heteromer
Q07869;
683-697
MMB;
Assess
X-ray structure of benzisoxazole urea synthetic agonist bound to the LXR-alpha Heteromer
Q13133;
682-696
O40;SO4;
Assess
Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid Heteromer
Q07869;
682-696
ET1;
Assess
Crystal Structure of PXR LBD Complexed with SJB7 Heteromer
O75469;
682-696
4WH;
Assess
Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 4 Heteromer
Q13133;
682-696
4KM;
Assess
Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 32b Heteromer
Q13133;
682-696
4KQ;
Assess
Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC180 and 9cRA and SRC1 Heteromer
P19793; Q96RI1;
685-699
9R3;9CR;
Assess
X-ray structure of human PPARalpha ligand binding domain-clofibric acid-SRC1 coactivator peptide co… Heteromer
Q07869;
683-696
E0O;
Assess
Crystal structure of HNF4a LBD in complex with the ligand and the coactivator SRC-1 peptide Heteromer
P41235;
687-700
MYR;
Assess
Crystal structure of PPARgamma with compound BR101549 Heteromer
P37231;
682-695
AE0;
Assess
X-ray structure of human PPARalpha ligand binding domain-fenofibric acid-SRC1 coactivator peptide c… Heteromer
Q07869;
684-696
F5A;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
744-756
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
744-756
9LS;
Assess
Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC143 and 9cRA and SRC1 Heteromer
P19793; Q96RI1;
686-698
9R0;SO4;9CR;PO4;
Assess
Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… Heteromer
Q96RI1;
744-756
OMM;
Assess
Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist Heteromer
Q96RI1;
744-756
643;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
744-756
643;
Assess
X-ray structure of human PPAR gamma ligand binding domain-seladelpar-SRC1 coactivator peptide co-cr… Heteromer
P37231;
684-696
KKB;
Assess
The 2.5 Angstrom resolution crystal structure of the human PPARalpha ligand binding domain bound wi… Heteromer
Q07869;
685-697
544;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9LA;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9MM;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9MY;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9LV;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9LP;
Assess
Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimida… Heteromer
Q96RI1;
744-755
OMK;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
CL;9L7;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9LG;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9O1;
Assess
Structural and Biochemical Mechanisms for the Specificity of Hormone Binding and Coactivator Assemb… Heteromer
P08235;
1430-1441
C0R;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
744-755
9N4;
Assess
Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2… Heteromer
Q96RI1;
745-756
OKI;
Assess
Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Rec… Heteromer
P19793; P37231;
629-640
9RA;D30;
Assess
Crystal structure of estrogen receptor beta complexed with 3-Bromo-6-hydroxy-2-(4-hydroxy-phenyl)-i… Heteromer
Q92731;
629-640
789;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9M7;
Assess
Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… Heteromer
Q96RI1;
745-756
OOF;
Assess
Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… Heteromer
Q96RI1;
745-756
OOK;
Assess
Crystal Structure of PPARg in complex with INT131 Heteromer
P37231;
629-640
Z12;CL;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-756
9N7;
Assess
X-ray structure of human PPAR gamma ligand binding domain-bezafibrate co-rystals obtained by co-cry… Heteromer
P37231;
685-696
PEM;
Assess
MR in complex with desisobutyrylciclesonide Heteromer
P08235;
1430-1441
DMS;GOL;SO4;CV7;
Assess
Crystal structure of LXR ligand binding domain in complex with full agonist 1 Heteromer
P55055;
745-756
0KS;ACT;CA;
Assess
Revealing a steroid receptor ligand as a unique PPARgamma agonist Heteromer
P37231;
685-696
486;
Assess
Crystal structure of FXR in complex with agonist XJ034 Heteromer
Q96RI1;
745-756
AWL;
Assess
Crystal structure of the agonist-bound ligand-binding domain of Biomphalaria glabrata RXR Heteromer
Q8T5C6;
687-698
9CR;
Assess
crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO Heteromer
P19793; Q14994;
686-697
F15;
Assess
crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-… Heteromer
P19793; Q14994;
686-697
F15;
Assess
Crystal structure of LXR ligand binding domain in complex with partial agonist 5 Heteromer
P55055;
745-756
0KT;ACT;CA;
Assess
FXR-LBD with HNC143 and SRC1 Heteromer
Q96RI1;
745-756
9R0;
Assess
Human Estrogen Receptor beta Ligand-binding Domain in Complex with S-DPN Heteromer
Q92731;
630-640
I0K;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with estradiol Heteromer
P03372;
686-696
EST;GOL;EDO;
Assess
a crystal structure of PPAR alpha bound with SRC1 peptide and GW735 Heteromer
Q07869;
686-696
735;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9NG;
Assess
Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R)-2-(2-chloro-4-hydroxyphenyl)… Heteromer
Q92731;
630-640
I1M;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
744-754
9ND;
Assess
Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… Heteromer
Q96RI1;
745-755
OLF;
Assess
Structure of human FXR in complex with MFA-1 and co-activator peptide Heteromer
Q96RI1;
685-695
YT3;MUF;
Assess
Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Heteromer
P37231;
686-696
CEK;
Assess
Crystal structure of RARb LBD homodimer in complex with TTNPB Heteromer
P10826;
686-696
TTB;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9MP;
Assess
Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Heteromer
P37231;
687-697
FCM;
Assess
Human Estrogen Receptor beta Ligand-binding Domain in Complex with (S)-3-(2-chloro-4-hydroxyphenyl)… Heteromer
Q92731;
630-640
I1I;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9N1;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW7647-SRC1 coactivator peptide co-crystal… Heteromer
Q07869;
686-696
2VN;
Assess
Human PPARgamma ligand binding domain complexed with Rosiglitazone Heteromer
P37231;
686-696
BRL;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
746-756
9MA;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9KV;
Assess
Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R)-3-(2-chloro-4-hydroxyphenyl)… Heteromer
Q92731;
630-640
I1D;
Assess
Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Heteromer
P37231;
686-696
24L;
Assess
Human PPARgamma ligand binding dmain complexed with S35 Heteromer
P37231;
686-696
T35;MYR;GOL;
Assess
VDR complex Heteromer
Q9PTN2;
686-696
AYK;
Assess
Allene-Based Design of a Noncalcemic Vitamin D Receptor Agonist Heteromer
Q9PTN2;
686-696
T0H;ACT;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9LM;
Assess
Human PPARgamma ligand binding domain complexed with Lobeglitazone Heteromer
P37231;
686-696
8LX;
Assess
CRYSTAL STRUCTURE OF FARNESOID X-ACTIVATED RECEPTOR COMPLEXED WITH COMPOUND-32 AKA (1S,3S)-N-({4-[5… Heteromer
Q96RI1;
746-756
IUS;
Assess
Human PPARgamma ligand binding domain complexed with SB1494 Heteromer
P37231;
686-696
A9F;
Assess
Vitamin D receptor complex Heteromer
Q9PTN2;
686-696
B0B;
Assess
Human Estrogen Receptor beta Ligand-binding Domain in Complex with (S)-2-(2-chloro-4-hydroxyphenyl)… Heteromer
Q92731;
630-640
I2B;
Assess
Crystal Structure of PPARgamma complexed with Telmisartan Heteromer
P37231;
686-696
TLS;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9NP;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9LY;
Assess
The ligand-free structure of human PPARgamma LBD R288H mutant in the presence of the SRC-1 coactiva… Heteromer
P37231;
686-696
MLI;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9M1;
Assess
Crystal structure of RARbeta LBD in complex with LG 100754 Heteromer
P10826;
686-696
754;FLC;GOL;
Assess
Human PPARgamma ligand binding dmain complexed with SB1453 in a covalent bonded form Heteromer
P37231;
686-696
T53;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
746-756
9NA;
Assess
FXR bound to a quinolinecarboxylic acid Heteromer
Q96RI1;
745-755
89P;SO4;
Assess
The ligand-free structure of human PPARgamma LBD Q286E mutant in the presence of the SRC-1 coactiva… Heteromer
P37231;
686-696
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9NJ;
Assess
The ligand-free structure of human PPARgamma LBD F287Y mutant in the presence of the SRC-1 coactiva… Heteromer
P37231;
686-696
MLI;
Assess
A novel moderator XD4 for bile acid receptor Heteromer
Q96RI1;
745-755
XD4;SO4;
Assess
Crystal structure of RARbeta LBD in complex with agonist BMS411 [4-{[(5,5-dimethyl-8-phenyl-5,6-dih… Heteromer
P10826;
686-696
1NY;PE4;FLC;
Assess
The agonist-free structure of human PPARgamma ligand binding domain in the presence of the SRC-1 co… Heteromer
P37231;
686-696
MYR;GOL;
Assess
The ligand-free structure of human PPARgamma LBD C285Y mutant in the presence of the SRC-1 coactiva… Heteromer
P37231;
686-696
MLA;
Assess
CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WI… Heteromer
P62508;
687-697
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9L4;
Assess
X-ray structure of human PPARalpha ligand binding domain-bezafibrate-SRC1 coactivator peptide co-cr… Heteromer
Q07869;
686-696
PEM;
Assess
Crystal structure of PPARgamma with compound BR102375K Heteromer
P37231;
685-695
GOL;A0L;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9LJ;
Assess
Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain Heteromer
Q9PTN2;
686-696
9CZ;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-755
9KY;
Assess
FXR with SRC1 and GW4064 Heteromer
Q96RI1;
745-755
064;
Assess
Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol Heteromer
P04150;
1431-1441
DAY;
Assess
FXR with SRC1 and GSK237 Heteromer
Q96RI1;
745-755
SO4;37G;
Assess
X-ray structure of human PPAR gamma ligand binding domain-fenofibric acid co-crystals obtained by c… Heteromer
P37231;
686-696
F5A;
Assess
The ligand-free structure of human PPARgamma LBD in the presence of the SRC-1 coactivator peptide Heteromer
P37231;
686-696
Assess
crystal structure of the RARalpha/RXRalpha ligand binding domain heterodimer in complex with a frag… Heteromer
P10276; P28700;
686-696
LG2;GOL;EQN;
Assess
FXR with SRC1 and GSK826 Heteromer
Q96RI1;
745-755
82X;SO4;
Assess
FXR-LBD with HNC180 and SRC1 Heteromer
Q96RI1;
745-755
SO4;9R3;
Assess
Crystal structure of RARbeta LBD in complex with selective agonist BMS948 [4-{[(8-phenylnaphthalen-… Heteromer
P10826;
686-696
JYH;FLC;
Assess
The ligand-free structure of human PPARgamma LBD R288C mutant in the presence of the SRC-1 coactiva… Heteromer
P37231;
686-696
Assess
X-ray structure of the orphan nuclear receptor ERR3 ligand-binding domain in the constitutively act… Heteromer
P62508;
687-697
Assess
The ligand-free structure of human PPARgamma LBD S289C mutant in the presence of the SRC-1 coactiva… Heteromer
P37231;
686-696
MLA;
Assess
Side-chain fluorine atoms of non-steroidal vitamin D3 analogs stabilize helix 12 of vitamin D recep… Heteromer
Q9PTN2;
686-696
MG;C5D;
Assess
Human PPARgamma ligand-binding domain R288A mutant in complex with imatinib Heteromer
P37231;
686-696
STI;
Assess
Identification of a unique PPAR ligand with an unexpected binding mode and antibetic activity Heteromer
P37231;
686-696
0W3;
Assess
Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… Heteromer
Q9PTN2;
686-696
0VK;
Assess
Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… Heteromer
Q9PTN2;
686-696
0VP;
Assess
FXR bound to isoquinolinecarboxylic acid Heteromer
Q96RI1;
745-755
P88;SO4;
Assess
FXR with SRC1 and GSK8062 Heteromer
Q96RI1;
745-755
O62;
Assess
FXR with SRC1 and GSK359 Heteromer
Q96RI1;
745-755
SO4;59G;
Assess
Crystal structure of human FXR/RXR-LBD heterodimer bound to GW4064 and 9cRA and SRC1 Heteromer
P19793; Q96RI1;
686-696
064;9CR;
Assess
FXR with SRC1 and GSK2034 Heteromer
Q96RI1;
745-755
SO4;034;
Assess
FXR with SRC1 and GSK088 Heteromer
Q96RI1;
745-755
088;SO4;
Assess
Ternary complex of hPPARalpha ligand binding domain, 17-oxoDHA and a SRC1 peptide Heteromer
Q07869;
686-696
4M5;
Assess
Characterization of ligands for the orphan nuclear receptor RORbeta Heteromer
P45446;
687-696
ARL;
Assess
Crystal structure of phosphorylated estrogen receptor beta ligand binding domain Heteromer
Q92731;
686-695
EST;
Assess
X-ray structure of human PPARalpha ligand binding domain-pemafibrate-SRC1 coactivator peptide co-cr… Heteromer
Q07869;
686-695
P7F;GOL;
Assess
X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-SRC1… Heteromer
Q07869;
686-695
PLM;GOL;
Assess
Mineralocorticoid receptor in complex with (s)-13 Heteromer
P08235;
1432-1441
GOL;EWN;
Assess
X-ray structure of human PPARalpha ligand binding domain-eicosapentaenoic acid (EPA)-SRC1 coactivat… Heteromer
Q07869;
686-695
EPA;GOL;
Assess
The structure of MR in complex with eplerenone. Heteromer
P08235;
1432-1441
YNU;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with 4-tert-octylphenol Heteromer
P03372;
687-696
27L;
Assess
Crystal structure of RARalpha ligand binding domain in complex with an agonist ligand (Am580) and a… Heteromer
P10276;
687-696
EQN;
Assess
Mineralocorticoid receptor in complex with (s)-13 Heteromer
P08235;
1432-1441
MPD;EY8;
Assess
The structure of MR in complex with AZD9977. Heteromer
P08235;
1432-1441
ECV;
Assess
MCR IN COMPLEX WITH ligand Heteromer
P08235;
1432-1441
6QG;NHE;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with TCBPA Heteromer
P03372;
687-696
XDH;GOL;
Assess
Human PPARgamma ligand binding dmain complexed with R35 Heteromer
P37231;
687-696
Q35;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with alpha-zearalanol Heteromer
P03372;
687-696
27J;GOL;EDO;
Assess
MCR IN COMPLEX WITH ligand Heteromer
P08235;
1432-1441
NHE;MPD;SO4;EDO;6Q0;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
747-756
9MD;
Assess
X-ray structure of the orphan nuclear receptor ROR beta ligand-binding domain in the active conform… Heteromer
P45446;
687-696
STE;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with HPTE Heteromer
P03372;
687-696
27N;GOL;EDO;
Assess
Crystal structure of RARbeta LBD in complex with selective partial agonist BMS641 [3-chloro-4-[(E)-… Heteromer
P10826;
687-696
JYI;FLC;
Assess
Fragment-Based Design of novel Estrogen Receptor Ligands Heteromer
Q92731;
686-695
W23;
Assess
Identification of a novel PPARg ligand that regulates metabolism Heteromer
P37231;
1432-1441
CTI;
Assess
1a,20S-dihydroxyvitamin D3 VDR complex Heteromer
Q9PTN2;
686-695
D3V;
Assess
A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG)… Heteromer
P37231;
631-640
RO0;GOL;
Assess
VDR complex of a side-chain hydroxylated derivatives of lithocholic acid Heteromer
Q9PTN2;
686-695
2WV;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
745-754
9MS;
Assess
MCR IN COMPLEX WITH ligand Heteromer
P08235;
1432-1441
EDO;6QE;
Assess
Design and biological evaluation of novel, balanced dual PPARa/g agonists Heteromer
P37231;
631-640
CTM;
Assess
MR in complex with dexamethasone Heteromer
P08235;
1432-1441
GOL;DEX;
Assess
Fragment-Based Design of novel Estrogen Receptor Ligands Heteromer
Q92731;
686-695
W14;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with chlordecone Heteromer
P03372;
687-696
EDO;27E;GOL;
Assess
Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain Heteromer
Q9PTN2;
686-695
91W;
Assess
VDR LBD complex with 25-nitro derivative of 1,25D3 Heteromer
Q9PTN2;
686-695
ACT;UYO;
Assess
Characterization of ligands for the orphan nuclear receptor RORbeta Heteromer
P45446;
687-696
REA;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with biochanin A Heteromer
P03372;
687-696
QSO;GOL;EDO;
Assess
Crystal Structure of Estrogen Receptor Beta Complexed with WAY-555 Heteromer
Q92731;
631-640
555;
Assess
Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists Heteromer
P37231;
631-640
208;
Assess
Vitamin D receptor complex with 25-amine derivative of 1,25D3 Heteromer
Q9PTN2;
686-695
ACT;UYU;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with ferutinine Heteromer
P03372;
687-696
27H;EDO;
Assess
VDR complex with a side-chain hydroxylated derivative of lithocholic acid Heteromer
Q9PTN2;
686-695
2UI;
Assess
Crystal structure of the LBD of VDR of Danio rerio in complex with calcitriol Heteromer
Q9PTN2;
686-695
VDX;
Assess
Human PPARgamma ligand binding dmain in complex with SR1664 Heteromer
P37231;
687-696
3JX;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
746-755
9M4;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
746-755
9L1;
Assess
Crystal structure of estrogen receptor beta ligand binding domain Heteromer
Q92731;
686-695
EST;
Assess
Fragment-Based Design of novel Estrogen Receptor Ligands Heteromer
Q92731;
686-695
WV7;
Assess
X-ray structure of human PPAR gamma ligand binding domain-lanifibranor-SRC1 coactivator peptide co-… Heteromer
P37231;
686-695
BJB;
Assess
RXRa structure complexed with CU-6PMN and SRC1 peptide. Heteromer
P19793;
687-696
WY5;
Assess
Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes Heteromer
P37231;
631-640
RO7;
Assess
Crystal structure of zVDR L337H mutant-VD complex Heteromer
Q9PTN2;
686-695
VDX;
Assess
Nuclear receptor DAF-12 from parasitic nematode Strongyloides stercoralis in complex with its physi… Heteromer
Q9XZJ5;
1432-1441
DL7;
Assess
Nuclear receptor DAF-12 from parasitic nematode Strongyloides stercoralis in complex with its physi… Heteromer
Q9XZJ5;
1432-1441
DL4;
Assess
Potent Vitamin D Receptor Agonist Heteromer
Q9PTN2;
686-695
M7E;
Assess
Vitamin D receptor complex Heteromer
Q9PTN2;
686-695
AYT;
Assess
X-ray structure of human PPAR gamma ligand binding domain-pemafibrate co-crystals obtained by co-cr… Heteromer
P37231;
686-695
P7F;
Assess
Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexy… Heteromer
Q96RI1;
746-755
OKH;
Assess
Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… Heteromer
Q9PTN2;
686-695
0VQ;
Assess
Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… Heteromer
Q9PTN2;
686-695
0VP;
Assess
Structure of lamprey VDR in complex with 1,25D3 Heteromer
S4R4S2;
686-695
VDX;MG;
Assess
Vitamin D nuclear receptor complex 1 Heteromer
Q9PTN2;
686-695
E05;
Assess
Ligand binding domain of PPARgamma complexed with a benzimidazole partial agonist Heteromer
P37231;
686-695
M0T;
Assess
Crystal structure of the ligand binding domain of the Vitamin D nuclear receptor in complex with Ge… Heteromer
Q9PTN2;
686-695
BIV;
Assess
VDR complex with Aromatic-D-Ring Analog Heteromer
Q9PTN2;
686-695
ACT;IV1;
Assess
VDR complex with aromatic D-ring analog Heteromer
Q9PTN2;
686-695
ACT;IV5;
Assess
Crystal structure of Vitamin D nuclear receptor ligand binding domain bound to a locked side-chain … Heteromer
Q9PTN2;
686-695
XE4;
Assess
The ligand-free structure of human PPARgamma ligand-binding domain R288A mutant in the presence of … Heteromer
P37231;
687-696
Assess
VDR complex with BXL-62 Heteromer
Q9PTN2;
686-695
U5W;
Assess
Human PPARgamma ligand binding dmain complexed with SB1405 in a covalent bonded form Heteromer
P37231;
687-696
B05;
Assess
Revealing a marine natural product as a novel agonist for retinoic acid receptors with a unique bin… Heteromer
P10276;
1432-1441
LUF;
Assess
Human PPARgamma ligand binding dmain complexed with SB1451 in a covalent bonded form Heteromer
P37231;
687-696
T51;
Assess
Crystal structure of zVDR L337H mutant-Gemini72 complex Heteromer
Q9PTN2;
686-695
H97;
Assess
Human PPARgamma ligand binding dmain complexed with SB1404 in a covalent bonded form Heteromer
P37231;
687-696
B4H;
Assess
Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain Heteromer
Q9PTN2;
686-695
9CW;
Assess
Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… Heteromer
Q9PTN2;
686-695
0VO;
Assess
Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… Heteromer
Q9PTN2;
686-695
484;
Assess
X-ray structure of human PPAR alpha ligand binding domain-lanifibranor-SRC1 coactivator peptide co-… Heteromer
Q07869;
687-696
Assess
VDR-ZK168281 complex Heteromer
Q9PTN2;
686-695
M9Q;
Assess
Structure of PPARalpha-LBD/pemafibrate/SRC1 peptide Heteromer
Q07869;
686-695
P7F;
Assess
X-ray structure of human PPAR alpha ligand binding domain-elafibranor-SRC1 coactivator peptide co-c… Heteromer
Q07869;
687-695
GOL;MUO;
Assess
Crystal structure of dimeric RXRalpha-LBD complexed with partial agonist CBt-PMN and SRC1 Heteromer
P19793;
687-695
9HF;CA;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with propylparaben Heteromer
P03372;
688-696
36M;GOL;EDO;PEG;
Assess
Retinoic acid receptor alpha mutant - N299H Heteromer
P10276;
687-695
5Z6;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with alpha-zearalenol Heteromer
P03372;
688-696
36J;GOL;EDO;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with butylparaben Heteromer
P03372;
688-696
27K;GOL;
Assess
Crystal Structure of the wild Human ROR gamma Ligand Binding Domain. Heteromer
G1RH57;
688-696
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
746-754
9NM;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-AF Heteromer
P03372;
688-696
0CZ;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with benzylbutylphtalate Heteromer
P03372;
688-696
27G;GOL;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with benzophenone-2 Heteromer
P03372;
688-696
27M;GOL;
Assess
Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-A Heteromer
P03372;
688-696
2OH;
Assess
CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697 Heteromer
Q92731;
632-640
697;
Assess
Crystal Structure of Estrogen Receptor beta complexed with WAY-338 Heteromer
Q92731;
632-640
338;
Assess
Vitamin D nuclear receptor complex 4 Heteromer
Q9PTN2;
687-695
DZT;
Assess
Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain. Heteromer
G1RH57;
688-696
Assess
VDR complex with BXL-62 Heteromer
Q9PTN2;
687-695
U5W;
Assess
Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPA… Heteromer
P19793; P37231; Q92793;
687-695
L79;570;
Assess
Crystal Structure of Estrogen Receptor beta complexed with WAY-797 Heteromer
Q92731;
632-640
797;
Assess
Vitamin D nuclear receptor complex 3 Heteromer
Q9PTN2;
687-695
LX3;
Assess
Ligand binding to FARNESOID-X-RECEPTOR Heteromer
Q96RI1;
747-755
9LD;
Assess
Crystal structure of estrogen receptor beta complexed with 1-chloro-6-(4-hydroxy-phenyl)-naphthalen… Heteromer
Q92731;
632-640
4NA;
Assess
Vitamin D nuclear receptor complex 2 Heteromer
Q9PTN2;
687-695
E0E;
Assess
Vitamin D receptor complex 5 Heteromer
Q9PTN2;
687-695
DZW;
Assess
Human PPARgamma ligand binding domain complexed with SB1495 Heteromer
P37231;
687-695
A9C;
Assess
VDR complex with LCA derivative Heteromer
Q9PTN2;
687-695
FKC;
Assess
Human PPARgamma ligand binding dmain complexed with SB1406 in a covalent bonded form Heteromer
P37231;
687-695
6BH;
Assess
Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 Heteromer
P37231;
687-694
3T0;
Assess
Structure of RORgt in complex with a novel agonist. Heteromer
P51449;
688-695
EDO;HOJ;
Assess
Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diab… Heteromer
Q07869;
746-753
RO7;
Assess
RORgamma (263-509) complexed with SRC2 and Compound 6 Heteromer
P51449;
688-695
4CX;
Assess
Crystal structure of RARb LBD in complex with 9cis retinoic acid Heteromer
P10826;
688-695
REA;
Assess
Design and biological evaluation of novel, balanced dual PPARa/g agonists Heteromer
Q07869;
746-753
CTM;
Assess
Novel natural PPARalpha agonist with a unique binding mode Heteromer
Q07869;
688-695
SAU;
Assess
Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with an Inhibitor 30a and GRI… Heteromer
P03372;
689-695
IAT;PEG;
Assess
Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with an Inhibitor 30o and GRI… Heteromer
P03372;
689-695
PEG;
Assess
The structure of human pregnane X receptor in complex with an SRC-1 coactivator peptide and a limon…homo-2-mer676-696
G3L;
Assess
STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR P…homo-2-mer678-698
L7D;
Assess
STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator p…homo-2-mer678-696
XGH;
Assess
PXR in complex with P2X4 inhibitor compound 25monomer678-699
GOL;DMS;
Assess
Tethered PXR-LBD/SRC-1p apoproteinmonomer678-696
Assess
Tethered PXR-LBD/SRC-1p complexed with SR-12813monomer678-696
SRL;
Assess
STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator p…monomer678-696
QCG;
Assess
PXR IN COMPLEX WITH THROMBIN INHIBITOR COMPOUND 17monomer681-698
GOL;MPD;PO4;
Assess
SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTSmonomer683-696
Z7D;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE…monomer683-696
Z7G;
Assess
SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTSmonomer683-696
TKJ;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE…monomer683-696
Z7I;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE…monomer683-696
Z7H;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS- RORGT(244-487)-L6-SRC1(678-692)) IN COMPL…monomer683-696
O5B;GOL;
Assess
Crystal structure of RAR-related orphan receptor C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) in comple…monomer683-696
O5A;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE…monomer683-696
Z8I;
Assess

5 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
4f3l.1.Amonomer0.5227-366
21.47
Assess
5sy5.1.Bmonomer0.5230-369
21.67
Assess
4f3l.1.Bmonomer0.5231-368
22.57
Assess
8osl.1.Lmonomer0.5127-365
22.05
Assess
7xi3.1.Amonomer0.5027-362
25.39
Assess

9 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 24f3l.1.Amonomer0.5227-366
21.47
Assess
Isoform 25sy5.1.Bmonomer0.5230-369
21.67
Assess
Isoform 24f3l.1.Bmonomer0.5231-368
22.57
Assess
Isoform 28osl.1.Lmonomer0.5127-365
22.05
Assess
Isoform 34f3l.1.Amonomer0.5227-366
21.47
Assess
Isoform 35sy5.1.Bmonomer0.5230-369
21.67
Assess
Isoform 34f3l.1.Bmonomer0.5231-368
22.57
Assess
Isoform 38osl.1.Lmonomer0.5127-365
22.05
Assess
Isoform 37xi3.1.Amonomer0.5027-362
25.39
Assess